Carl Domino held its stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,601 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Gilead Sciences accounts for 1.5% of Carl Domino’s investment portfolio, making the stock its 21st largest position. Carl Domino’s holdings in Gilead Sciences were worth $1,882,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the stock. Commonwealth Equity Services raised its stake in shares of Gilead Sciences by 17.8% in the fourth quarter. Commonwealth Equity Services now owns 266,055 shares of the biopharmaceutical company’s stock worth $26,922,000 after buying an additional 40,158 shares during the last quarter. Hills Bank & Trust Company raised its stake in shares of Gilead Sciences by 123.8% in the fourth quarter. Hills Bank & Trust Company now owns 6,290 shares of the biopharmaceutical company’s stock worth $636,000 after buying an additional 3,480 shares during the last quarter. Skylands Capital raised its stake in shares of Gilead Sciences by 9.7% in the fourth quarter. Skylands Capital now owns 28,900 shares of the biopharmaceutical company’s stock worth $2,924,000 after buying an additional 2,550 shares during the last quarter. Rhenman & Partners Asset Management raised its stake in shares of Gilead Sciences by 7.8% in the fourth quarter. Rhenman & Partners Asset Management now owns 124,000 shares of the biopharmaceutical company’s stock worth $12,548,000 after buying an additional 9,000 shares during the last quarter. Finally, Tompkins Financial raised its stake in shares of Gilead Sciences by 234.1% in the fourth quarter. Tompkins Financial now owns 13,917 shares of the biopharmaceutical company’s stock worth $1,408,000 after buying an additional 9,751 shares during the last quarter.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 89.63 on Thursday. The company’s 50 day moving average price is $97.87 and its 200-day moving average price is $105.51. The company has a market capitalization of $129.17 billion and a price-to-earnings ratio of 8.23. Gilead Sciences, Inc. has a 1-year low of $86.00 and a 1-year high of $123.37.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $3.22 EPS for the quarter, beating the consensus estimate of $2.87 by $0.35. During the same quarter in the prior year, the business posted $1.84 earnings per share. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.84 billion. The business’s revenue for the quarter was up 37.3% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post $12.21 earnings per share for the current year.

A number of brokerages have recently commented on GILD. Needham & Company LLC reissued a “buy” rating and set a $125.00 price target on shares of Gilead Sciences in a research note on Wednesday. JPMorgan Chase & Co. reissued an “overweight” rating and set a $133.00 price target on shares of Gilead Sciences in a research note on Wednesday, January 13th. Oppenheimer reissued a “buy” rating and set a $124.00 price target on shares of Gilead Sciences in a research note on Wednesday, October 28th. Piper Jaffray reissued a “buy” rating and set a $134.00 price target on shares of Gilead Sciences in a research note on Saturday, January 9th. Finally, Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $119.36 price objective for the company in a research report on Friday, November 13th. Eight equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $125.10.

In other Gilead Sciences news, CEO John C. Martin sold 150,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $109.42, for a total transaction of $16,413,000.00. Following the sale, the chief executive officer now directly owns 3,948,066 shares in the company, valued at approximately $431,997,381.72. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of the stock in a transaction on Monday, January 4th. The shares were sold at an average price of $99.20, for a total value of $198,400.00. Following the sale, the executive vice president now owns 48,783 shares in the company, valued at $4,839,273.60. The disclosure for this sale can be found here.

Gilead Sciences, Inc. (NASDAQ:GILD), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

12 Month Chart for NASDAQ:GILD

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.